Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.61 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
| ▸ | CCR8 | P51685 | 2/20 | 0.52 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NCK1 | P16333 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404737 | 0.91 | CYP1A2 (0.61) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL8404528 | 0.91 | CYP1A2 (0.61) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL21632461 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL18266965 | 0.80 | CYP1A2 (0.64) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL2320872 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL1028024 | 0.78 | CYP2A6 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL16488083 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL18574471 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL7990724 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL1563936 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463469-B1 | COMBINATION OF LEDIPASVIR AND SOFOSBUVIR FOR USE IN THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS IN HUMANS | GILEAD SCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022199256-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-111777553-B | Preparation method of isoquinoline compounds | 苏州大学 | 2022-03-18 | — | — | CN | disclosed |
| EP-1857521-B2 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEM CORP (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090066223-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-1857521-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | Mitsubishi Chemical Corporation (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2004064842-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | CYP1A2 2808/4885CYP2A6 2755/4885CCR1 329/4885 |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | CYP1A2 3253/4885CYP2A6 3362/4885CCR1 3348/4885 |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CYP1A2 2220/4885CYP2A6 3013/4885CCR1 4195/4885 |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | BRCA1, VHL, TFEB | CYP1A2 1097/4885CYP2A6 662/4885CCR1 4755/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | CYP1A2 3219/4885CYP2A6 3698/4885CCR1 3494/4885 |
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | CYP1A2 1655/4885CYP2A6 1111/4885CCR1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.